Beijing Luzhu Biotechnology Co Ltd
02480
Company Profile
Business description
Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group's product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
Contact
No. 3 Guangtong Street
Industrial Development Zone, Zhangjiawan Tongzhou District
Beijing
CHNT: +86 1061568561
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
213
Stocks News & Analysis
stocks
ASX tech share upgraded following AI contract wins
Strong demand for AI infrastructure drives fair value lift.
stocks
5 star fully franked ASX dividend payer
Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,969.70 | 83.10 | 0.94% |
| CAC 40 | 8,035.87 | 42.61 | -0.53% |
| DAX 40 | 25,399.21 | 24.79 | 0.10% |
| Dow JONES (US) | 51,349.92 | 131.59 | -0.26% |
| FTSE 100 | 10,636.71 | 48.17 | -0.45% |
| HKSE | 24,510.56 | 13.01 | -0.05% |
| NASDAQ | 26,797.54 | 22.84 | -0.09% |
| Nikkei 225 | 66,318.81 | 837.54 | 1.28% |
| NZX 50 Index | 13,819.40 | 135.77 | 0.99% |
| S&P 500 | 7,670.84 | 12.85 | -0.17% |
| S&P/ASX 200 | 8,791.90 | 82.60 | 0.95% |
| SSE Composite Index | 3,840.71 | 10.26 | 0.27% |